GlassScriptPhysician profile
Dushyant Parikh
NPI 1023033008
$8,621.27
in general payments reported to CMS, 2019-2025
44 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $820 · 2021: $2,007 · 2022: $1,626 · 2023: $1,766 · 2024: $1,178 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,163 · Education: $5.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,163.41 |
| Education | $5.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,874.57 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,053.50 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $811.46 | 2020-2025 | Bevespi Aerosphere, Airsupra, Breztri |
| Eisai INC. | $542.04 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $450.11 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.85 | 2020-2025 | Jardiance |
| Pfizer INC. | $385.38 | 2021-2025 | |
| Novo Nordisk INC | $275.48 | 2020-2024 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $275.27 | 2022-2025 | Caplyta |
| Amgen INC. | $244.82 | 2020-2025 | Repatha, Otezla |
| Lilly USA, LLC | $197.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $183.73 | 2023-2025 | Rexulti |
| Corium, LLC | $181.27 | 2022-2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.34 | 2021-2025 | Xifaxan |
| Amarin Pharma, INC. | $151.95 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dushyant Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.